Targeted Oncology Staff

During a virtual Targeted Oncology Case-Based Roundtable event, Rodolfo Bordoni, MD, discussed recent clinical trials in the extensive-stage small cell lung cancer space.

Melissa Alsina, MD, reviewed the treatment options for transplant-eligible multiple myeloma based on the case of a 52-year-old male patient.

Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel P. Petrylak, MD, discussed the case of a 66-year-old woman with metastatic bladder cancer.

Ezra Cohen, MD, lead a discussion on the efficacy of cemiplimab-rwlc for the treatment of cutaneous squamous cell carcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Lori Wirth, MD, discussed the treatment patients with radioiodine-refractory differentiated thyroid cancer with a group of peers.

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

An accelerated approval was granted by the FDA to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

During a virtual Targeted Oncology Case-Based Roundtable event, Kartik Konduri, MD, discussed the case of a 58-year-old patients with small cell lung cancer.

Thomas Hutson, DO, PharmD, discussed the case of a 66-year-old patient with bladder cancer during a virtual Targeted Oncology Case-Based Roundtable event.

Vivek Subbiah, MD, explored the treatment options for RET-fusion positive non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, lead a debate with a group of peers on second-line therapy options for patients with renal cell carcinoma.

Schlafen-11 expression may serve as a predictive biomarker for response to select treatments in patients with small cell lung cancer.

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.

Joshi Alumkal, MD assessed the available checkpoint inhibitors for the treatment of mutated metastatic castration-resistant prostate cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, led a peer discussion about frontline treatment of a patient with differentiated thyroid cancer.

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

Thomas G. Martin, MD discussed the case of a patient with newly-diagnosed multiple myeloma during a virtual Targeted Oncology Case-Based Roundtable event.

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.

During a virtually held Targeted Oncology Case-Based Roundable event, Meghan Mooradian, MD, discussed the case of a 63-year-old patient diagnosed with non–small cell lung cancer.

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Eleni Efstathiou, MD, PhD, discussed the case of a 75-year-old patients with metastatic castration-resistant prostate cancer.

Jessica Donnington, MD, led a discussion with a group of peers regarding treatment of non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.

During a virtual Targeted Oncology Case-Based Roundtable, Ajai Chari, MD. a professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York, NY, discussed the case of a 72-year-old patient with multiple myeloma.

During a virtual Targeted Oncology Case-Based Roundtable event, Anish B. Parikh, MD, discussed front-line treatment options for metastatic urothelial cancer as well as the data supporting avelumab maintenance.